Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secutrelvir in High-Risk COVID-19 Participants
NCT07743580Phase 3Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Countries
- 3
01
Overview
A Phase 3 trial of secutrelvir in coronavirus disease 2019 (COVID-19), sponsored by Shionogi & Co., Ltd.. Started Sep 2026; status: recruiting.
02
Drugs
secutrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07743580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743580.